|
Daily Medical Update
Procedure- and device-associated infections
Sunday, September 27, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Frontiers in public health (2026) - Meta-Analysis
Key Findings
- Across 34 observational studies involving approximately 8,901 patients, immunosuppression increased nosocomial-infection odds (OR 2.21), as did inter-hospital transport (OR 2.24) and pre-ECMO infection (OR 2.54).
- Risk also increased with higher SOFA score (OR 1.13 per point), longer ECMO duration (OR 1.10 per day), continuous renal replacement therapy (OR 2.18), and catheter intubation (OR 1.24); age, BMI, diabetes, and hypertension were not significant predictors.
📋 Practice Implication: ECMO infection prevention should use a risk-stratified bundle that prioritizes pre-ECMO infection control, transport minimization, and intensified surveillance during prolonged or renal-replacement-supported runs.
|
The Journal of hospital infection (2026) - Systematic Review
Key Findings
- Standard contact precautions plus episodic chemical disinfection used alone had a pooled operational failure and recontamination proportion of 0.708 (95% CI 0.559-0.830).
- Proactive containment was associated with a 79% reduction in transmission risk (RR 0.21, 95% CI 0.12-0.37), while targeted withdrawal of highly handled reusable fomites had the strongest outbreak-termination effect (RR 0.08).
📋 Practice Implication: For Candida auris outbreaks, infection-control programs should pair rapid admission molecular screening with aggressive management of reusable high-touch fomites instead of relying on reactive disinfection alone.
|
Critical care medicine (2026) - Meta-Analysis
Key Findings
- In 11 randomized trials involving 5,562 patients, systemic prophylactic antibacterials probably reduced overall VAP (RR 0.65, 95% CI 0.55-0.77) and early VAP (RR 0.52, 95% CI 0.41-0.66).
- They probably did not reduce in-hospital mortality (RR 0.85, 95% CI 0.68-1.06) or ventilation duration, and no increased risk of drug resistance or adverse events was observed, although safety reporting was incomplete.
📋 Practice Implication: Systemic prophylaxis may be considered selectively for VAP prevention, but it should not be promoted as a mortality intervention and should be accompanied by resistance surveillance and stewardship review.
|
Gastroenterologia y hepatologia (2026) - Guideline
Key Findings
- The position paper emphasizes individualized management and strategies to reduce the high recurrence burden of healthcare-associated C. difficile infection.
- Its treatment algorithm links disease severity and initial versus recurrent episodes to therapy and includes fecal microbiota transplantation as a recurrence-reducing option.
📋 Practice Implication: CDI pathways should explicitly separate initial from recurrent disease, incorporate severity-based treatment, and ensure access to recurrence-directed options such as fecal microbiota transplantation when appropriate.
|
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026) - Guideline
Key Findings
- The guideline suggests switching clinically improving cUTI patients to an effective oral antibiotic when they can take medication, even when Gram-negative bacteremia is present.
- Oral and parenteral completion strategies provide similar efficacy and adverse-event profiles without increased adverse-event burden, while an early switch can reduce intravenous catheter-related adverse events, costs, and resource use.
📋 Practice Implication: Once clinical improvement, oral tolerance, and an active tissue-penetrating oral option are confirmed, cUTI care should favor IV-to-oral transition to limit catheter exposure without sacrificing treatment efficacy.
|
|
💡
Summary
The highest-priority evidence identifies infection risk in ECMO patients from baseline infection, immunosuppression, illness severity, transport, and prolonged or intensive support, while proactive containment substantially reduced Candida auris transmission. In mechanically ventilated patients, systemic prophylactic antibacterials reduced VAP but not mortality, and the included guidance supports individualized recurrence-focused CDI care and early IV-to-oral therapy for improving complicated UTI patients, including those with Gram-negative bacteremia.
|
|